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Abstract: The tear film represents the interface between the eye and the environment. The alteration
of the delicate balance that regulates the secretion and distribution of the tear film determines the dry
eye (DE) syndrome. Despite having a multifactorial origin, the main risk factors are female gender and
advanced age. Likewise, morphological changes in several glands and in the chemical composition
of their secretions, such as proteins, mucins, lipidics, aqueous tears, and salinity, are highly relevant
factors that maintain a steady ocular surface. Another key factor of recurrence and onset of the
disease is the presence of local and/or systemic inflammation that involves the ocular surface. DE
syndrome is one of the most commonly encountered diseases in clinical practice, and many other
causes related to daily life and the increase in average life expectancy will contribute to its onset.
This review will consider the disorders of the ocular surface that give rise to such a widespread
pathology. At the end, the most recent therapeutic options for the management of DE will be briefly
discussed according to the specific underlying pathology.
Keywords: dry eye; lacrimal gland; lipids and lipidomics; Meibomian gland; ocular surface disorders;
proteins and proteomics; tear film
1. Introduction
Dry eye (DE) syndrome, or keratoconjunctivis sicca, is an autoimmune disorder of the ocular
surface that affects more than 35% of the population [1], and most frequently the female gender.
It consists of qualitative and quantitative alteration of the tear film, whose main function is lubrification,
nutrition, optical transparency, cleanliness, and as the main defense to bacterial infections, both corneal
and conjunctival.
The Dry Eye Workshop (DEWS) in 2007 defined DE as a multifactorial disease of tears and ocular
surface that results in symptoms of discomfort, visual disturbance, and tear film instability with
potential damage to the ocular surface, which is accompanied by increased osmolarity of the tear film
and inflammation of the ocular surface [2].
The most common symptoms of the disease are burning, foreign body sensation, photophobia,
itching, stinging, irritation, redness, blepharospasm, difficulty in opening eyelids on awakening, and,
in severe cases, pain and blurred vision. Symptoms are subjective and increase in special environmental
conditions, such as wind exposure, dry heat, and low humidity, and in the presence of contact lens
(CL), smoking, air conditioning, or heating (Table 1). Each specialized layer of the ocular surface
contributes to a component of the tear film (Figure 1). In fact, the lacrimal and accessory glands
produce the central nutritive aqueous component; the Meibomian glands (MGs) produce the oily outer
lipid that provides tear film stability; and the conjunctival mucipare goblet cells (GCs) produce the
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inner “surfactant” mucin that primarily improves the wettability of the ocular surface. The eyelids
and lashes provide fundamental protection through the blink mechanism, wipe away debris from
the ocular surface, and replenish the surface with a fresh layer of tears. Among these various factors,
the dysfunction of MGs is one of the most frequent causes found in DE.
Table 1. Dry eye symptoms and diagnostic tests.
Common Dry Eye Symptoms
Irritation Burning or stinging sensation
Dryness or grittiness Foreign body sensation
Itching and Redness Tearing
Fluctuation of vision Contact lens intolerance
Increased blinking frequency Blurry vision
Photophobia Mucous discharge
Dry Eye Diagnostic Tests
Tear Break Up Time (BUT) Tear film meniscus height
Ocular surface staining with fluorescein,
lissamine green, and rose bengal dye Schirmer test I and II
Other tests: tear film osmolarity, lactoferrin, lysozyme immunoglobulin, and albumin
dosage, and impression cytology.
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In this review, we have deepened the pathogenetic (Table 2), biochemical, and biophysical
mechanisms responsible for DE. We have also reported new therapeutic models in relation to the
causes of tear discomfort.
Table 2. Dry eye (DE) classification according to pathogenetic analysis in ocular surface disorders.
Meibomian Glands
Dysfunction
Principal
Mixed Forms
Other Major
Mixed Forms Aqueous Deficits
Ocular Surface
Diseases
Primary or DE
blepharitis syndrome
(DEBS). Secondary to
skin diseases such as
rosacea, psoriasis,
lupus, ichthyosis,
rheumatoid
arthritis, etc.
Oxidative stress,
aging and/or
associated factors.
Corneal
hypoesthesia.
Systemic/topical
medications,
conjunctivochalasis,
abnormal eyelid
position, etc.
Hormonal changes,
menopause, pregnancy.
Allergic diseases,
bacterial or viral
conjunctivitis, use of
contact lenses or
computer, ocular surface
trauma or tumor or
surgery, environmental
factors, etc.
Autoimmune
pathologies:
Sjögren’s syndrome
dry eye (SS).
Non-Sjögren’s
syndrome dry eye
(non-SSDE)
Stevens Johnson
syndrome (SJS), toxic
epidermal necrolysis
(TEN), graft-versus-host
disease (GVHD).
Neurotrophic
deficiencies,
Keratoconus (KC),
pinguecula, pterygium,
corneal dystrophies, etc.
2. Methods
A literature study of relevant publications about DE syndrome was performed. Through
a computerized search for review, several relevant articles in the PubMed database, published between
2000 and 2017, were identified. Key words used for the search included: “Dry eye” or “Ocular
surface disorders” or “Keratoconjunctivitis sicca” or “Sjögren’s syndrome” and “Tear film” and
“Lacrimal gland” or “Meibomian gland” or “Lipids and lipidomics” and “Protein and proteomics”
and “Treatment” or “Therapy phase II study”. Potentially eligible articles were clinical trials or review
articles pertinent to treatment for DE and written in English. Relevant articles were manually searched
and reviewed, and data concerning DE were included in the manuscript.
2.1. Dysfunction of Meibomian Glands
2.1.1. Primary Dysfunction of Meibomian Glands
The dysfunction of MGs is the most frequent cause of evaporative DE disease. MGs are localized
at the level of the upper and lower eyelids, and secrete lipids on the ocular surface, which form
the outermost layer of the tear film, with a lubrification function during blinking and a protection
function against tear evaporation [4,5]. In 2011, the International Workshop for MGs dysfunction
defined the evaporative DE disease “as a chronic, diffuse abnormality of MGs, characterized by
terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion” [6].
The probable cause of this pathology is due to a meibum stasis secondary to the obstruction, secretion,
and inflammation of MGs that favors bacterial growth. This could lead to an increase in the release of
esterase and lipase by commensal bacteria of the eyelids. As a consequence of this increased enzyme
activity, the bacteria change the meibum’s viscosity, leading to further stagnation of meibum within the
MGs and generating free fatty acids, which in turn cause inflammation and hyperkeratinization [4,7].
This change of the lipid composition leads to the appearance of foam in the tear film, often visible on the
eyelid margin of patients with MG dysfunction [8,9]. The absence of the normal meibum also would
reduce the lipid content of the tear film, entering in the vicious circle of DE disease, in which the lipid
deficiency of the tear film promotes increased tear evaporation, hyperosmolarity, and inflammation.
Furthermore, an infection with commensal bacteria, such as Staphylococcus aureus, is one of the causes
of chronic blepharitis. Recent studies suggested that a new term be used to describe it as single, chronic
disease called “Dry eye blepharitis syndrome” (DEBS) [10]. It is an inflammatory condition of the
eyelid margin previously considered synonymous with MGs dysfunction, but, in recent years, has been
recognized as a distinct clinical condition that may develop in the later stages of MGs dysfunction,
or independently where DE is the ultimate manifestation of other ocular surface disease.
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2.1.2. Secondary Dysfunction of Meibomian Glands to Chronic Inflammation
Skin diseases, such as rosacea, seborrheic dermatitis, or psoriasis, etc., also play a role in the
pathophysiology of MG dysfunction. Rosacea is a chronic skin disorder that affects the sebaceous
glands, especially at the level of the face. It is characterized by erythema, telangiectasia, facial
rash, inflammatory papules, and occasionally the hypertrophy of connective tissue [11]. It is more
common in people aged between 50 and 60 years [11,12], and the ocular manifestations may be
associated with skin manifestations or may appear independently. Although the etiology is uncertain,
the latest findings show that microbial pathogenesis and the mechanisms associated with chronic
inflammation and autoimmune dysregulation may be involved. The primary defect in ocular rosacea is
MG inflammation with dilatation and obstruction of the gland orifices leading to chronic dysfunction.
Chronic inflammation can lead to hyperkeratinization of the ductal epithelium, a loss of secretion, and
then to blepharitis, meibomitis, chalasia, telangiectasias, and eyelid irregularities [13].
This stimulates the inflammatory cells to release cytokines and activators of matrix
metalloproteinases (MMP) leading to ocular surface damage [14,15]. Subsequently, punctate
keratopathy and the superficial vascularization of peripheral cornea are also commonly found [12,13].
2.2. Dysfunction of Meibomian Glands and Aqueous Deficit: Mixed Forms
2.2.1. Aging and Lacrimal Discomfort
Another major risk factor for DE is age. Modifications of MG structure have been identified
with age as an altered localization of the peroxisome proliferator-activated receptor-γ (PPAR-γ),
a lipid-activated hormone receptor that regulates lipid synthesis and cell differentiation [16,17] or
MG atrophy [18]. Changes in the mucocutaneous junction and glandular atrophy through a loss of
meibocyte progenitors have been found in a mouse model [18]. Aging, in fact, leads to a decrease of the
acinar diameter and an increase in acinar wall inhomogeneity without significant modifications of the
glandular orifice diameter, altering qualitatively the meibum secretion. This is in agreement with the
main clinical changes observed during aging, represented by tear break up time (BUT) and Schirmer
test scores reduction. Moreover, with aging, we observe the atrophic involution of the glandular
unit, and then a progressive dysfunction of the secretive activity. This appears to be in line with the
involution of most parts of secretive structures, such as exocrine glands and lymphatics, observed in
several tissues of the human body during aging [19].
2.2.2. Aging and Associated Factors
Advanced age is also often associated with several factors.
1. The chronic use of systemic medications, such as antidepressants, diuretics, dopamine such as those
used for Parkinson's disease, and anti-metabolites commonly used to treat rheumatoid arthritis.
Depending on their mechanism of action, these drugs affect lacrimal secretion. In Parkinson’s
patients, for example, dopaminergic dysfunction is thought to play a role in decreasing the blink
reflex that leads to DE, in addition to a physiological decrease of corneal sensitivity with age that
increases the risk of exposure keratopathy. In addition, the decrease in liver and kidney function
lengthens the clearance time of systemic drugs.
2. The chronic use of topical medications as for glaucoma. β blockers, α-adrenergics, and
prostaglandins can reduce tear production. They can cause chronic irritation of the ocular
surface that compromises the integrity of the lacrimal glands. It has been highlighted that
a reduction of glandular density and area, and increased viscosity of the meibum, can occur.
In addition, the presence of preservatives, such as benzalkonium chloride (BAK), can cause tear
film instability, GCs loss, conjunctival squamous metaplasia and apoptosis, disruption of the
corneal epithelium barrier, and damage to deeper ocular tissues even at low concentrations [20].
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3. Abnormalities in the eyelid positioning, as laxity, floppy eyelid syndrome, retraction, entropion,
ectropion, and lagophthalmos. Horizontal lid laxity is the most common cause of involutional
eyelid malposition. Eyelid malposition leads to corneal exposure, poor tear-film distribution, and
abnormal tear outflow. As many as 50–70% of patients with this disease develop tear discomfort
syndrome [21].
4. Conjunctivochalasis is another notable contributor to poor tear outflow, and is characterized by a
redundant bulbar conjunctiva interposed between the globe and the eyelid [22]. Pathogenesis
of conjunctivochalasis is under investigation; however, elastotic degeneration from cumulative
sun exposure and inflammatory degeneration from delayed tear film clearance have been
proposed [23]. Once formed, the redundant folds interfere with the inferior tear meniscus,
and in some cases cause the occlusion of the inferior punctum.
5. A gradual reduction in corneal sensitivity has been shown to occur with increasing age, which
predisposes older adults to DE. Roszkowska et al. reported that the mechanical sensitivity of
the peripheral cornea decreases gradually throughout life, whereas central corneal sensitivity
remains stable until 60, and then decreases sharply subsequently [24].
6. Oxidative stress, a counterpart of inflammation, occurs when antioxidants are unable to counteract
reactive oxygen species (ROS) that are generated in normal metabolic processes. The production
of aggressive oxygen species, such as free radicals and peroxides, leads to DNA damage over
time, inducing cell necrosis and the impairment of the regenerative capacity of the corneal
epithelial cells. In younger, healthy subjects, low levels of ROS are counteracted by antioxidant
enzymes [25].
2.3. Aqueous Deficits in Autoimmune Diseases: Sjögren’s Syndrome and Non-Sjögren’s Syndrome Dry Eye
The DEWS divided aqueous deficits in two subclasses: Sjögren’s syndrome (SS) and non-Sjögren’s
Syndrome Dry Eye (non-SSDE). SS is a chronic inflammatory disorder characterized by exocrine gland
dysfunction. Lymphocytic infiltration of the lacrimal and salivary glands results in the classic sicca
complex characterized by DE (keratoconjunctivitis sicca or xeroftalmia) and dry mouth (xerostomia).
It can also affect the skin, trachea, vagina, nose, and throat. Patients with DE associated with SS
have been found to have elevated levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α)
in their tears [26]. The IL-6 level is associated with disease severity, and was found to correlate
with tear film and ocular surface parameters, e.g., tear film, lacrimal meniscus, BUT, Schirmer test,
tear clearance, GC density, and keratoepithelioplasty score [26]. Recently, Zhu et al. found that the
co-stimulatory molecules Ox40 and Ox40L on peripheral blood mononuclear cells are higher in Sjögren
patients than in normal controls, and their levels correlated with clinical outcome and therapeutic
response [27]. Even in patients with severe SS, biopsy specimens have revealed that 50% of glandular
cells are still present. These results emphasize the importance of immune factors, such as cytokines,
MMP, and autoantibodies, in decreasing neurosecretory circuits and inducing glandular dysfunction.
The keratoconjunctivitis in SS is classically described as an aqueous tear deficiency. However, in more
recent years, this assumption has been challenged. Some studies suggest that pathologic changes
induce global tear dysfunction, including alterations in MG function [28]. An analysis of patients
affected with SS with aqueous tear deficiency compared to non-SSDE with aqueous tear deficiency
demonstrated increased evaporation and also decreased MG secretion, with a deficient lipid layer in the
first group [28]. A new laser scanning confocal microscopy approach recently found some differences
in the MGs’ features among patients with primary SS, non-SSDE, and MG disease [27–29]. In fact,
the pattern of inhomogeneity of the MGs’ walls and interstices was markedly higher in all groups of
patients than in controls, with features more pronounced in primary SS compared to non-SSDE. This
inhomogeneous appearance varies with the level of inflammation, which is significantly higher in
eyes with SS, because of the autoimmune pathogenesis of this condition. The presence of confocal
signs of inflammation in the absence of dilative morphologic changes supports the presence of an
inflammatory/atrophic nonobstructive MG disease in primary SS [30,31]. Diagnosis of SS is generally
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based on the American-European Consensus Group (2002), and requires at least four out of six criteria,
or three out of the four objective criteria. The six criteria include subjective and objective ocular
dryness, subjective and objective oral dryness, the presence of Sjogren-specific antibodies A (SSA)/RO
and antibodies B (SSB)/LA, and a positive minor salivary gland biopsy [32]. However, in 2012, new
classification criteria for SS were approved by the American College of Rheumatology, which require at
least two of the following three criteria: positive serum anti-SSA and/or anti-SSB or rheumatoid factor
or antinuclear antibody, a total ocular surface staining score >3, and the presence of focal lymphocytic
sialadenitis with a focus score >1/4 mm2 in labial salivary gland biopsy samples [33]. According to the
classification criteria from the European-American collaboration, secondary SS consists of the features
of primary SS together with other features of an overt autoimmune connective tissue disease, the most
common of which is rheumatoid arthritis. There is a known association between DE syndrome and
several systemic diseases, such as SS, rheumatoid arthritis, scleroderma, polymyositis, lymphoma,
amyloidosis, hemochromatosis, sarcoidosis, and systemic lupus erythematosus [34]. In particular,
rheumatoid arthritis presents the greatest risk of ocular complications, such as scleritis, DE, and
peripheral ulcerative keratitis [35].
2.4. Other Major Causes of Mixed Forms
2.4.1. Hormonal Changes
DE disease affects women more frequently than men. Women are more likely to experience DE
disease during certain periods of significant hormonal alteration, for example, during pregnancy,
lactation, oral contraceptive use, and after menopause, suggesting that DE may be related to sex
hormones [36–39]. Receptors for androgens, progesterone, estrogen, and prolactin have been found in
several ocular tissues, including the lacrimal gland and MG [36–39]. Androgens are steroid hormones
that are produced by the adrenals (testosterone, androstanediol, dehydroepiandrosterone sulfate
(DHEAS), dehydro-epiandrosterone (DHEA), androstenedione (A)), gonads (T), and peripheral tissues
(dihydrotestosterone (DHT)). Experimental and human studies have demonstrated that androgen
levels are essential for normal lacrimal gland function and structural organization, and that prolactin
and estrogen also plays an important role in providing adequate hormone provision for optimal
lacrimal production [39–41]. In particular, the androgen receptor influences the MGs; this has led to
the hypothesis that these glands are under hormonal control. Androgens, in fact, act on epithelial
acinar cells that contain receptors for messenger RNA and/or protein receptors for androgens. These
cells respond to androgens by binding them to a specific lipid-producing area on the cell surface,
which then transcribes specified genes that increase the lipid layer’s distribution over the ocular
surface [36–39]. In particular, Suzuki et al. [38] demonstrated that testosterone stimulates genes related
to lipid metabolic pathways and suppresses genes regulating epithelial keratinization.
Moreover, the estrogen produced after menopause derives primarily from the peripheral
conversion of adrenal androgens to oestrone in the liver, kidney, brain, and adrenal and peripheral
adipose tissue. The absolute levels of oestrogen are influenced by weight, sex, and age [39].
In postmenopause, androgens continue to be produced by the ovarian stromal cells and hilus cells
in response to the increased levels of circulating lutein hormone [39]. The data suggest that sex
hormone deficiency may not only cause a reduction in the production of aqueous tears, leading to
a deficiency, but also a dysfunction in the MG function, resulting in an evaporative DE. In women
with complete androgen insensitivity syndrome due to androgen receptor dysfunction, an alteration
in the neutral and polar lipid patterns of human MG secretion along with the keratinization of the
MG ductal epithelium (i.e., orifice metaplasia) and the lid has been observed [38–41]. Particularly in
these women, there is a significant increase in signs and symptoms of DE. Not surprisingly, a high
incidence of evaporative DE disease was found in hyperandrogenic women affected by polycystic
ovarian syndrome [40,41]. This allows us to speculate that a perfect balance between androgens and
estrogens is necessary to maintain a stable tear film [40,41].
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2.4.2. Use of Contact Lenses, Computers, and Interactive Environments
The over use of CL may highly increase the risk of a syndrome of tear film dysfunction. The main
observed findings are a decreased basal epithelium cell density, reduced acinar unit diameters, higher
glandular orifice diameters, greater secretion reactivity, and greater inhomogeneity of the periglandular
interstices. Morphologic changes in the MGs shown by CL wearers were interpreted by the authors as
signs of MGs dropout, duct obstruction, and glandular inflammation caused by chronic mechanical
CL irritation [12,19,20,30]. In such cases, therefore, it is recommend to use low or medium lenses
hydration that would release the liquid, retaining its geometry, high permeability of oxygen, and the
use of monodose artificial tears viscous.
Environments characterized by high temperatures, high humidity, wind, smoke, smog, and air
conditioning result in a greater rate of tear evaporation. The prolonged use of computer screens,
fixation efforts, and the top position of the screen which increases the exposed ocular surface are all
factors that may increase tear film evaporation, while the decreased frequency of blinking will reduce
tear film stability and efficiency.
2.4.3. Dry Eye and Allergic Diseases
Allergic diseases are among the most common ocular surface disorders, and allergy is one of
the most frequent eye problems that occurs in clinical practice. The prevalence of allergic diseases in
children between 6 and 14 years varies from 0.3 to 20.5%, and is gradually increasing [42]. This is due
to genetic factors, environmental pollution, and exposure to the sun in children. The most common
form of allergy is seasonal allergic conjunctivitis (AC), while vernal keratoconjunctivitis (VKC) is
considered a rare disease in Europe, most frequently affecting children within the second decade
of life. VKC is a serious pediatric multifactorial illness, which compromises the quality of life of
children, and can lead to severe ocular symptoms, with giant papillae on the upper tarsal conjunctiva
(cobblestoning appearance), and gelatinous infiltrations to the limbus surrounding the cornea, called
Horner–Trantas dots. If untreated, ocular surface remodeling leads to corneal ulcers and scars [43].
VKC can be associated with other serious disorders of allergic or autoimmune nature, such as asthma
or collagenopathies [43].
There are many examples in the literature that link the dysfunction of the lacrimal film with chronic
forms of AC. Pflugfelder et al. [44] suggested that activated T-cells and an increase in inflammatory
cytokines, such as epidermal growth factor, IL-1, and IL-8, may damage GCs and the conjunctival
epithelium, leading to a reduction of mucin production and subsequent decrease of tear film BUT.
These inflammatory changes cause macroscopic modifications of the MG, represented by
glandular atrophy and ductal dilatation. The same morphofunctional alterations were described
in seasonal AC, where we observe a significant decrease in the size and density of MG acinar units.
MGs appear small and irregular with periglandular fibrosis and a restricted and not well-defined
lumen, and occluded by a hyper-reflective and dense meibum [45–47]. In addition to the instability of
the tear film, another risk factor is the use of antihistamines in the long term that have anticholinergic
properties due to their high affinity for the muscarinic receptor [45–47].
2.4.4. Dry Eye and Refractive/Cataract Surgery
Laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) are the two most
commonly performed corneal surgeries used to correct refractive errors. Negative effects on the tear
film are known to occur after both procedures, despite a full achievement of the refractive result.
Consequently, tear substitutes are needed in the first few postoperative months [48].
The same occurs in cataract surgery. Indeed, Li et al. have analyzed the pathogenic factors
in 37 patients, and they have found that the incidence of dry eye increases dramatically after
phacoemulsification [49]. The number of patients who had positive corneal and conjunctival fluorescein
staining increased after surgery (16 patients; 22 eyes). The fluctuations and/or decrease of Schirmer
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test score, BUT, and average density of globet cells in conjunctiva followed a pattern which was in
accordance with the observed symptoms of dry eye, and they were significantly worse than before
cataract surgery. The ocular discomfort at 1 month was present in 14.7% of the patients; the score
reached a peak at 1 month after surgery and decreased gradually after 3 months [49].
Yu and colleagues found that 95% of patients who underwent LASIK had DE symptoms during
the first postoperative day, and 85% continued to experience symptoms during the first postoperative
week. Over 60% of patients still had complaints of DE at the first postoperative month [50]. These
symptoms improved over the course of several months, with reported rates of DE disease at 6 months
ranging from 12 to 48% [51]. The incidence of DE symptoms after PRK is similar to that after LASIK
except in the early postoperative period. Indeed, immediately after PRK, patients have a high level of
discomfort due to the epithelium damage. Later symptoms are comparable to the post-LASIK setting.
Stephenson and colleagues showed that only 20% of patients post PRK complained of DE at 6 months,
and in a 12-year study [52] only 3% of patients had symptoms of DE [53].
The genesis of postrefractive DE depends on the type of technique, which causes injury to the
nerve plexus leading to neurotrophic deficits. In LASIK, the nerve plexus is compromised by the
execution of the corneal flap, and the nervous integrity is preserved only at the level of the hinge.
Further damage is related to the extent of ablation and to the refractive correction. In PRK, injury to
the nerve endings involves the entire surface ablation, and is correlated with the ablation’s depth and
therefore with the amount of the refractive defect.
In cataract surgery, the damage is related to corneal and limbal incisions. The damage to
the nervous plexus impairs corneal sensitivity that eventually reduces blinking, increases tear film
evaporation, and alters the stimulation of tear production. [54]. The disruption of corneal innervation
also lead to a loss of epitheliotropic factors, such as substance P, which have an important role for
epithelial regeneration and integrity. Nerve Growth Factor (NGF) levels are reduced after LASIK
or PRK, inducing a possible neurotrophic epithelial disease [55,56]. The increased evaporation or
reduced tear production leads to an increase of tear osmolarity and inflammatory changes on the ocular
surface. The mediators, released by damage to the nerve endings and cells after corneal photoablation,
cause the degranulation of mast cells and the recall of the leukocytes, monocytes, and macrophages
determining blood vessel dilation and tissue hypersensitivity [57,58].
In addition, the modification of the corneal profile alters the interaction between the upper eyelid
and corneal curvature, resulting in an irregular tear distribution during blinking [59,60]. Despite
that the phenomena related to the nervous trophism tend to be exhausted 6–8 months after surgery,
the symptoms may persist for a longer time because of partial nerve plexus recovery or pre-existing
nerve plexus pathologies. Therefore, adequate preoperative screening is required to identify and avoid
refractive surgery in patients with compromised conditions.
2.5. Tear Film and Specific Pathologies of the Ocular Surface
2.5.1. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, immunologic
dermato-bullous conditions with high morbidity and mortality that affect the skin and at least two
mucous membranes. The diagnosis is made through clinical signs and a skin biopsy demonstrating
full-thickness necrosis of the epidermis and keratinocyte apoptosis, with minimal involvement of the
underlying dermis. SJS is defined when the denuded cutaneous surface covers less than 10% of the
body surface area, and TEN is when over 30% of the body surface area is denuded. The etiology of
the diseases, in addition to genetic susceptibility, is immune-mediated and can be triggered by drugs
(most commonly sulfonamides, allopurinol, carbamazepine, etc.), or, less commonly, by systemic
viral or mycoplasma pneumonia infection. The ocular surface represents one of the major targets
in this disease, and patients may become irreversibly blind. Ocular surface inflammation can be
intense, with pseudomembrane or membrane formation, symblepharon, corneal ulceration, and
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perforation. Acute ocular manifestations led to chronic ocular sequelae with visual impairment
in at least one-third of patients. Ectropion, entropion, trichiasis, distichiasis, corneal epithelial
defects, infection, neovascularization, loss of conjunctival goblet cells, meibomian gland atrophy
and thickening, keratinization of the eyelid margin, and tarsal and bulbar conjunctival surfaces can
be associated. Scarring in the fornices and in the lacrimal gland ducts causes severe aqueous and
mucous lipid tear deficiency and xerosis. Resultant corneal blindness due to the absence of tears,
eyelid malpositions, and tarsal conjunctival keratinization is the most dreaded long-term complication
among SJS/TEN survivors. These changes not only cause debilitating pain in affected patients, but also
threaten vision and are correlated with the development of late corneal blindness, due in part to chronic
limbal stem cell dysfunction (LSCD). In general, SJS and TEN are considered T-cell mediated, type IV
hypersensitivity disorders. There are elevated levels of TNF-α in the blister fluid, skin, mononuclear
cells, and blood of affected patients. TNF-α activates TNF-R1, which leads to the activation of the
Fas-associated death domain protein and downstream caspase pathways. Furthermore, human
ocular surface epithelial cells strongly express toll-like receptor 3 (TLR3), and its ligand, polyI:C.
These were found to induce various molecules, such as proinflammatory cytokines and antiviral-
and allergy-related molecules, in the SJS/TEN population. To conclude, keratinocyte and epithelial
cell death in SJS/TEN appears to occur by apoptosis, thus, several mechanisms are likely involved
to varying degrees. Similar findings have characterized the autoimmune response in patients with
chronic graft-versus-host disease (GVHD), one of the major causes of morbidity and mortality in
patients undergoing allogenetic hematopoietic stem cell transplantation for hematologic malignancies.
In this setting, we may find glandular dysfunction from glandular atrophy and fibrosis [61–63].
2.5.2. Keratoconus
Keratoconus (KC), by definition, is a progressive disorder characterized by non-inflammatory
corneal ectasia and stromal thinning that leads to corneal surface distortion [64,65]. The etiology of
this disease remains unknown, although there is evidence of a genetic origin, and it can be associated
with systemic diseases [64,65]. Eighty percent of patients suffering from KC have tired eye, irritation,
and a foreign body sensation, suggesting ocular dryness [64]. In fact, while the amount of the aqueous
component remains comparable to that of healthy eyes, in functional studies evaluating the tear ducts
of patients with KC, BUT values tests correlate to the disease’s severity. The conical morphology of
the cornea with an abnormal distribution of tears, the alteration of the quality/quantity of mucin
secretion, and the reduction of GCs would lead to tear film instability [64]. Recently, the level of
adenosine tetraphosphate (Ap4A) was proposed as a potential molecular biomarker for DE. Ap4A is
assessed by chromatography on a strip used for the Schirmer test. Ap4A concentration in tears increases
proportionally to DE severity, and patients with KC have concentrations 20 times higher than in healthy
eyes [64]. The impression cytology reveals a high degree of squamous metaplasia in the conjunctival
epithelium, and a marked reduction of GCs, detected in combination with confocal microscopy.
Another finding is the abnormal relationship between the cornea and the ocular surface–eyelid
complex, which is also caused by the more pronounced tendency of patients with KC to rub their
eyes. The morphological and functional alteration leads to an abnormal distribution of an already
altered tear film. The proof is given by fluorescein and rose bengal tests; the increase of corneal
accumulation of these dyes is directly related to the ocular surface damage in patients with KC [65].
Several studies report a reduction in corneal sensitivity in patients with KC, especially in those using
CL. This is related to morphological and structural changes of the cornea, and to the alterations of
the lacrimal function [66,67]. Moreover, histopathological and confocal microscopy-based studies
demonstrated a decrease and an abnormal morphology of sub-basal and stromal nerves of the cornea
in patients with KC, especially near the apex. This alteration tends to decrease, especially towards
the corneal periphery [67]. The altered structure is related, in particular, to the cold thermoceptors,
which are reduced in number and in a chronic excitatory state. This alteration together with tear film
hyperosmolarity seems to be one of the main causes of reduced sensitivity in DE.
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Furthermore, reduced levels of lactoferrin, immunoglobulin A, and lipofilina A and C together
with elevated levels of serum albumin have been found in the tears of patients with KC, suggesting
the presence of inflammatory processes on the ocular surface [68]. Increased levels of MMP-1, MMP-3,
MMP-7, and MMP-9 have also been found in subjects with KC compared to healthy individuals [67,68].
MMPs are enzymes responsible for the degradation of the matrix of extracellular proteins, and are
secreted in response to cytokines (IL-4, IL-5, IL-6, and IL-8) and growth factors (TNF-α and TNF-β).
2.5.3. Pterygium
Pterygium is a common disease of the ocular surface characterized by fibrovascular tissue growth
from the bulbar conjunctiva to the cornea. It may lead to chronic ocular irritation, astigmatism, tear
film disorders, and decreased vision secondary to the growth of the lesion over the visual axis [69,70].
Although the exact etiology is unknown, exposure to ultraviolet (UV) radiation is believed to be
the main risk factor [69,70]. Age, chronic inflammation, microtrauma, and hereditary factors can
contribute to the growth of pterygium [70,71]. Studies show that the genetic trauma mediated by UV
rays could alter the expression of cytokines, such as IL-6 and IL-8, in patients with pterygium [69].
IL-6 and IL-8 can induce the production of MMPs, which have been found in the advanced stage
of the disease [70]. The release of IL-6, IL-8, and MMP in the tear film could lead to damage to
surface and tear film instability, resulting in apoptosis of epithelial cells, GC loss, reduction of mucous
secretion, and lacrimal hyperosmolarity [70,71]. Finally, it develops a vicious circle in which the tear
hyperosmolarity stimulates the expression of MMPs leading to inflammation of the ocular surface [71].
A study shows that the excision of pterygium increases conjunctival GCs density and the lacrimal
mucous component, improving both the osmolarity and the stability of the tear film, and consequently
the BUT [72]. However, tear osmolarity tends to remain stable until the pterygium’s recurrence.
2.6. Up-To-Date on Biochemical Mechanisms in Dry Eye Disease
It is now established that DE is a disease caused by an inflammatory process that disrupts the
normal homeostasis of the ocular surface. Thus, a common pathogenic mechanism of DE is related to
the tear hyperosmolarity that can activate a chain of events resulting in a vicious circle of inflammation,
which leads to further ocular surface injury (Figure 2). As a result, high levels of chemokines,
macrophage inflammatory proteins (MIP-1α), cytokines (IL-1β), MMP, TNF-α, lymphocytes infiltration,
and an increase of conjunctival human leukocyte antigen expression (HLA-DQ and HLA-DR),
CD40 protein, CD40 ligand ICAM-1 (cell surface receptors), and apoptotic marker APO2.7 have
been demonstrated in DE patients [73]. In fact, studies have confirmed the anti-inflammatory
effects of CF-101, an A3 adenosine receptor (A3-AR) agonist, that binds to A3-AR and mediates
the downregulation of the nuclear factor kappa-light-chain-enhancer of activated B cells-TNF-α
(NF-κB-TNF-α) B-TNF-α) signaling pathway, the inhibition of cytokines secretion, and inflammatory
cells apoptosis [73]. It has been suggested that the improvement of several pathological signs and
symptoms in subjects with DE, such as Schirmer test and BUT scores, might be due to a reduction
in ocular surface inflammation following direct interaction between CF101 and its receptors on
inflammatory cells [73].
Furthermore, other recent studies have highlighted the essential role of inflammatory mediators.
Since Omega 3 (ω3) and Omega 6 (ω6) are considered polyunsaturated fatty acids (PUFAs), they
are defined as “essential” and they cannot be synthesized by the human body; ω3 and ω6 derive
from α-linolenic acid and linoleic acid, respectively, and they are precursors of eicosanoids with
potential anti-inflammatory (ω3 group) and proinflammatory effects (ω6 group). An equilibrate
balance between ω3 and ω6 is necessary to avoid the prevalence of an ω6 proinflammatory effect.
In particular, proresolving lipid mediators derived from ω-3 precursors, such as docosahexaenoic
acid (DHA) and eicopentaenoic acid (EPA), control epithelial wound healing, inflammatory cell
migration, and nerve regeneration [74,75]. The prostaglandins, belonging to a class of inflammatory
lipid mediators called eicosanoids, are derived from the oxygenation of arachidonic acid (AA) andω-6
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that is enzymatically released from the cell membranes of activated cells in response to environmental
stress. The release of AA and the subsequent generation of eicosanoid lipid mediators is responsible for
triggering the acute inflammatory response to corneal injury [73]. However, its resolution is mediated
by proresolving lipid mediators derived from theω-3 PUFA precursors DHA and EPA. Consequently,
it is hypothesized that DE is a metabolic disorder characterized by an imbalance ofω-3 andω-6 PUFA
leading to the underproduction of proresolving lipid mediators.Int. J. Mol. Sci. 2017, 18, 1764  11 of 19 
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Figure 2. Dry eye results in the inflammatory response to diseases, infections, and damage of the
ocular surface, and tear hyperosmolarity can activate a chain of events resulting in a vicious circle
of inflammation of the anterior eye. Successively, the release of proinflammatory molecules secreted
by several cells leads to the recruitment of immune cells as well as a disruption of the ocular surface.
Interleukin-1-4-5-6-8 (IL-1-4-5-6-8); tumor necrosis factor-α (TNF-α); tumor necrosis factor-β (TNF-β);
metalloproteases-3-7-9 (MMP-3-7-9); macrophage inflammatory proteins (MIP-1α); conjunctival human
leukocyte antigen expression (HLA-DQ; HLA-DR); cell surface receptors (CD40 protein, CD40 ligand
ICAM-1); prostaglandin-E (PG-E).
Corneal epithelial cells and resident regulatory polymorphonuclear (PNMs) leukocytes in the
corneal limbus and lacrimal gland highly express 15-lipoxygenase (15-LOX), a key enzyme for the
generationg and release of specialized proresolving mediators, which are critical for the control of
the immunity of the ocular surface. Endogenous lipoxin A4 promotes corneal epithelial wound
healing [76], inhibits pathological angiogenesis and proinflammatory cytokine expression [77,78], and
controls effector T-cell activation [79]. Neuroprotectin D1 is implicated in epithelial cell survival [80],
recovery from oxidative stress, and wound healing [81]; it has also been shown to promote corneal
nerve regeneration and corneal sensitivity restoration [81,82]. Resolvin E1 exerts proresolving effects
directly through G-protein-coupled receptors [83] and indirectly through negative feedback on
cyclooxygenase-2 (COX-2) expression, which plays an important role in the synthesis of prostaglandins
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from arachidonic acid [84]. It has been shown that these mediators are essential for the homeostasis of
the tear film, the survival of GCs, and the secretion in response to stress. This underlines the biological
significance of ω-3 proresolving lipid mediators in the tear film, and supports the hypothesis that
DE has a metabolic basis. The nutritional or metabolic deficiency of DHA and EPA may lead to an
underproduction of lipid mediators in tears. A higher ratio of ω-6 lipid mediators of ω-3 induces
the inflammation of the ocular surface. Recent studies and a meta-analysis of randomized controlled
trials support the supplement ofω-3 fatty acids for DE syndrome; oral administration ofω-3 improves
Schirmer Test and BUT scores (Figure 3) [81–84].
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2.7. Therapeutical Pragmatic Approach
The purpose of recent research was to promote ocular surface health by reducing the inflammation
and stabilizing the tear film. Although several therapeutic approaches for DE are available, therapeutic
strategies, such as the use of artificial eye lubricants, focus on the treatment of symptoms guaranteeing
just temporary relief to the patient without having an effect on the implicit causes of DE [12]. The DEWS
report suggests that a clinician choose specific treatments based on the severity of the disease according
to patients’ clinical history and experience [2]. Nowadays, treatments of DE include the use of
lubricating eye drops, unguents, dietary supplements associated with eyelid cleaning, and in severe
cases with punctual occlusion and topical and oral non-steroidal anti-inflammatory (NSAID) and
corticosteroid drugs.
2.7.1. Topical onsteroidal nti-Infla atory ( SI )
S I and steroids are usually evaluated for SS even if a prolonged use of steroids ay be
associated with severe side effects such as the onset of cataract, infections, and a high level of intraocular
pressure [12]. Currently, there are few NSAIDs that do not seem to cause toxic effects on the cornea;
however, they could lead to DE by reducing eye corneal sensitivity [85,86].
Pranoprofen and bromfenac sodium ophthalmic solution are NSAIDs with an anti-inflammatory
effect due to the inhibition of epoxidase and synthesis of arachidonic acid (AA). These drugs improved
signs and symptoms, and reduced conjunctival human leukocyte antigen II (HLADR) expression in
patients, also in cases where patients were unresponsive to lubricant monotherapy [85,86].
Thymosin β4 is a naturally occurring 43 amino acid peptide found in high concentrations in most
tissues, cells, blood plasma, and ocular surface fluid. Thymosin β4 possesses both wound-healing
and anti-inflammatory properties [12,87]. This drug has been shown to have a positive effect on
epithelial migration and healing, as well as an anti-inflammatory effect through a number of different
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pathways in vitro, in patients with diabetic neurotrophic corneal defects, and in severe DE as well as
graft-versus-host disease (GVHD), SJS, and TEN [61,63,87].
2.7.2. New Topical Natural Substance
Proteoglycan 4 (PRG4), also called lubricin, is an amphiphilic glycoprotein which plays a critical
role as a boundary lubricant in several sites throughout the body [88,89].
Some studies have discovered the presence of lubricin mRNA in a number of exocrine and
reproductive tissues. This superficial zone protein, containing a 1404 amino acid core, is produced
by ocular surface epithelium, and acts in protecting the cornea and conjunctiva against shear forces
generated during an eyelid blink [88,89].
A deficit of this glycoprotein, a natural boundary lubricant, promotes shear stress on the ocular
surface and increases damage. Conversely, the exogenous application of lubricin significantly reduces
the friction between the cornea and conjunctiva. In a recent clinical trial, the researchers stated that the
efficacy and safety of recombinant human lubricin compared to a 0.18% hyaluronic acid (HA) eye drop
in 39 subjects with moderate DE [89,90].
2.7.3. Secretagogues
Different topical pharmacologic agents may potentially increase both aqueous and mucin secretion.
Some preclinical studies have demonstrated the efficacy of Nerve Growth Factor in DE. In fact, NGF
supports the lacrimal function, stimulating the secretion of glycoconjugates from conjunctival cells and
promoting corneal homeostasis. NGF’s trophic function is related to tyrosine kinase receptor (TrkA)
and p75 neurotrophin receptor (p75 NTR) stimulation. The presence of both TrkA and NGF on the
ocular surface highlights their role in promoting ocular homeostasis. By binding TrkA, NGF stimulates
the release of mucin by the GCs of the conjunctiva, stabilizing the tear film [91].
MIM-D3 is a small protein-like chain designed to mimic NGF; it activates the TrkA receptor, but is
not able to bind the p75NTR receptor. In a Phase II clinical trial, Meerovitch et al. demonstrated
a considerable improvement in the signs and symptoms of DE, with both 1% and 5% MIM-D3
ophthalmic solutions. The 1% solution was related to the best result in fluorescein and lissamine green
corneal and conjunctival staining, respectively [91].
More recently, 3% diquafosol tetrasodium, a P2Y2 purinergic receptor agonist, has been launched
as an ophthalmic solution in Asian countries. It acts through a novel pathway by activating P2Y2
receptors of the ocular surface, and stimulating the quantity and quality of tear fluid secretion,
as determined by optical coherence tomography (OCT) and meniscometry in DE [92].
Diquafosol also stimulates the secretion of sialic acid, which is a mucin-like substance, in tears in
healthy subjects after a single dosing. Therefore, clinical trials demonstrated a good safety profile with
clinical improvement of the ocular surface in severe DE patients [92,93].
2.7.4. Topical Immunomodulators
Cyclosporine A (0.05–2%), a lipophilic cyclic polypeptide, is the first topical immunomodulator
in ophthalmic emulsion approved by the U.S. FDA in 2002 and by the European Union in 2015.
Cyclosporine A acts as an immunosuppressive agent when administered systemically. It has been
used topically for blepharitis, dry eye, keratoconjunctivitis, post LASIK, GVHD, SJS, and TEN [94–97].
It has been shown to inhibit the production and/or release of proinflammatory cytokines and
to upregulate the release of anti-inflammatory cytokines [94,96]. Moreover, cyclosporine A inhibits
the apoptosis and the amount of Fas-ligand expression in the infiltrating lymphocytes of human
conjunctival epithelial cells [96,97]. The U.S. FDA approved on 11 July 2016 the first medication of a
new class of drugs for the treatment of DE. Lifitegrast, in topical administration, is a novel integrin
antagonist which inhibits proinflammatory T-cell activity by T-cell adhesion to intercellular adhesion
molecule-1 (ICAM-1) [94,98].
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2.7.5. Systemic Therapy
Some studies have investigated the effects of dietary integration with PUFAs as a possible
substitutive therapy in the management of DE. The authors concluded that a metabolic deficiency
of ω3 tear film lipids can cause an inflammatory impact on the ocular surface, and this could lead
to chronic inflammation in DE subjects. Further large-scale, multicenter studies are necessary to
establish the guidelines for the administration and dosing of PUFAs [12]. Recently, new biologic
agents targeting B-cells, such as rituximab, belimumab, and epratuzumab, have shown promising
results in the treatment of autoimmune and progressive conditions such as SS. Achievements with
rituximab, monoclonal antibody directed against CD20, and other B-cell-depleting therapies, such as
interferon-α (INF-α) and anti-B-cell-activating factor (BAFF), have shown potential benefit even in
severe DE [99–102]; thus, further studies are needed to validate the findings in these patients.
3. Conclusions
DE syndrome consists of a wide spectrum of disorders with different causes. Nowadays, artificial
tears that guarantee a transient improvement of DE patients’ symptoms represent the first and most
frequently used therapy for a distressing condition that significantly impacts quality of life. However,
untreated inflammation can lead to severe and permanent complications. The aim of new medications
is to affect the various pathogenetic factors involved in the onset of DE. Nevertheless, new clinical
trials have demonstrated the effectiveness of stem cell transplantation-based treatments from human
embryonic stem cells (hESCs), which induce pluripotent stem cell (iPSC) growth [103,104]. Stem
cells hold promise for treating severe eye diseases, as the eye is an ideal organ for such an approach,
due to its relative immunological privilege, surgical accessibility, and the fact that it is a self-contained
system [87,103,104].
A multidisciplinary approach based on both topical and systemic therapies should be considered
for the clinical management of DE in order to obtain sustained relief for patients. Further studies are
needed to investigate the long-term effects of these new therapies planned for eventual treatment of
this chronic multivariate disease.
Author Contributions: Marcella Nebbioso and Paola Del Regno wrote the paper; Marta Sacchetti also wrote
the introduction and conclusion; Magda Gharbyia provided editing; Rocco Plateroti and Alessandro Lambiase
provided critical review.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Chia, E.M.; Mitchell, P.; Rochtchina, E.; Lee, A.J.; Maroun, R.; Wang, J.J. Prevalence and associations of dry
eye syndrome in an older population: The Blue Mountains Eye Study. Clin. Exp. Ophthalmol. 2003, 31,
229–232. [CrossRef] [PubMed]
2. Dogru, M.; Foulks, G.N.; Kinoshita, S.; Laibson, P.; McCulley, J.; Murube, J.; Pflugfelder, S.C.; Rolando, M.;
Toda, I. The definition and classification of dry eye disease: Report of the definition and classification
subcommittee of the international dry eye workshop (2007). Ocul. Surf. 2007, 5, 75–92.
3. Lemp, M.A.; Crews, L.A.; Bron, A.J.; Foulks, G.N.; Sullivan, B.D. Distribution of acqueous-deficient and
evaporative dry eye in a clinic-based patient cohort: A retrospective study. Cornea 2012, 31, 472–478.
[CrossRef] [PubMed]
4. Knop, E.; Knop, N.; Millar, T.; Obata, H.; Sullivan, D.A. The International Workshop on Meibomian Gland
Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian
Gland. Investig. Ophthalmol. Vis. Sci. 2011, 52, 1938–1978. [CrossRef] [PubMed]
5. Mc Culley, J.P.; Shine, W.E. Meibomian gland function and the tear lipid layer. Ocul. Surf. 2003, 1, 97–106.
[CrossRef]
6. Nichols, K.K.; Foulks, G.N.; Bron, A.J.; Glasgow, B.J.; Dogru, M.; Tsubota, K.; Lemp, M.A.; Sullivan, D.A. The
international Workshop on Meibomian Gland Dysfunction: Executive Summar. Investig. Ophthalmol. Vis. Sci.
2011, 52, 1922–1929. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1764 15 of 19
7. International Dry Eye Workshop. Report of the International Dry Eye Workshop (DEWS). Ocul. Surf. 2007, 5,
61–204.
8. Butovich, I.A.; Lu, H.; McMahon, A.; Ketelson, H.; Senchyna, M.; Meadows, D.; Campbell, E.; Molai, M.;
Linsenbardt, E. Biophysical and morphol ogical evaluation of human normal and dry eye meibum using hot
stage polarized light microscopy. Investig. Ophthalmol. Vis. Sci. 2014, 55, 87–101. [CrossRef] [PubMed]
9. Borchman, D.; Foulks, G.N.; Yappert, M.C.; Bell, J.; Wells, E.; Neravetla, S.; Greenstone, V. Human Meibum
lipid conformation and thermodynamic changes with Meibomian gland dysfunction. Investig. Ophthalmol.
Vis. Sci. 2011, 52, 3805–3817. [CrossRef] [PubMed]
10. Rynerson, J.M.; Perry, H.D. DEBS—A unification theory for dry eye and blepharitis. Clin. Ophthalmol. 2016,
10, 2455–2467. [CrossRef] [PubMed]
11. Steinhoff, M.; Schauber, J.; Leyden, J.J. New insights into rosacea pathophysiology: A review of recent
findings. J. Am. Acad. Dermatol. 2013, 69, S15–S26. [CrossRef] [PubMed]
12. Nebbioso, M.; Fameli, V.; Gharbiya, M.; Sacchetti, M.; Zicari, A.M.; Lambiase, A. Investigational drugs for
the treatment of dry eye disease. Expert Opin. Investig. Drugs 2016, 25, 1437–1446. [CrossRef] [PubMed]
13. Steinhoff, M.; Schmelz, M.; Schauber, J. Facial Erythema of Rosacea—Aetiology, different pathophysiologies
and treatment options. Acta Derm. Venereol. 2016, 96, 579–586. [CrossRef] [PubMed]
14. Solomon, A.; Dursun, D.; Liu, Z.; Xie, Y.; Macri, A.; Pflugfelder, S.C. Pro-and anti-inflammatory forms of
interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Investig. Ophthalmol. Vis. Sci.
2001, 42, 2283–2292.
15. Maatta, M.; Kari, O.; Tervahartiala, T.; Peltonen, S.; Kari, M.; Saari, M.; Sorsa, T. Tear fluid levels of MMP-8
are elevated in ocular rosacea-treatment effect of oral doxycycline. Graefes Arch. Clin. Exp. Ophthalmol. 2006,
244, 957–962. [CrossRef] [PubMed]
16. Nien, C.J.; Massei, S.; Lin, G.; Nabavi, C.; Tao, J.; Brown, D.J.; Paugh, J.R.; Jester, J.V. Effects of age and
dysfunction on human Meibomian glands. Arch. Ophthalmol. 2011, 129, 462–469. [CrossRef] [PubMed]
17. Nien, C.J.; Paugh, J.R.; Massei, S.; Wahlert, A.J.; Kao, W.W.; Jester, J.V. Age-related changes in the Meibomian
gland. Exp. Eye Res. 2009, 89, 1021–1027. [CrossRef] [PubMed]
18. Parfitt, G.J.; Xie, Y.; Geyfman, M.; Brown, D.J.; Jester, J.V. Absence of ductal hyper-keratinization in mouse
age-related Meibomian gland dysfunction (ARMGD). Aging 2013, 5, 825–834. [CrossRef] [PubMed]
19. Wei, A.; Hong, J.; Sun, X.; Xu, J. Evaluation of age-related changes in human palpebral conjunctiva and
meibomian glands by in vivo confocal microscopy. Cornea 2011, 30, 1007–1012. [CrossRef] [PubMed]
20. Baudouin, C.; Labbe, A.; Liang, H.; Pauly, A.; Brignole-Baudouin, F. Preservatives in eyedrops: The good,
the bad and the ugly. Prog. Retin. Eye Res. 2010, 29, 312–334. [CrossRef] [PubMed]
21. Damasceno, R.W.; Osaki, M.H.; Dantas, P.E.; Belfort, R., Jr. Involutional entropion and ectropion of the lower
eyelid: Prevalence and associated risk factors in the elderly population. Ophthal. Plast. Reconstr. Surg. 2011,
27, 317–320. [CrossRef] [PubMed]
22. Meller, D.; Tseng, S.C. Conjunctivochalasis: Literature review and possible pathophysiology. Surv. Ophthalmol.
1998, 43, 225–232. [CrossRef]
23. Di Pascuale, M.A.; Espana, E.M.; Kawakita, T.; Tseng, S.C. Clinical characteristics of conjunctivochalasis with
or without aqueous tear deficiency. Br. J. Ophthalmol. 2004, 88, 388–392. [CrossRef] [PubMed]
24. Roszkowska, A.M.; Colosi, P.; Ferreri, F.M.B.; Galasso, S. Age-related modifications of corneal sensitivity.
Ophthalmologica 2004, 218, 350–355. [CrossRef] [PubMed]
25. Dogru, M.; Wakamatsu, T.; Kojimaetal, T. The role of oxidative stress and inflammation in dry eye disease.
Cornea 2009, 28, S70–S74. [CrossRef]
26. Yoon, K.C.; Jeong, I.Y.; Park, Y.G.; Yang, S.Y. Interleukin-6 and tumor necrosis factor-α levels in tears of
patients with dry eye syndrome. Cornea 2007, 26, 431–437. [CrossRef] [PubMed]
27. Zhu, R.; Jiang, J.; Wang, T.; Xu, T.; Wu, M.; Liu, C.; Zhang, X. Expressions and clinical significance of OX40
and OX40L in peripheral blood of patients with primary Sjögren’s syndrome. Xi Bao Yu Fen Zi Mian Yi Xue
Za Zhi 2013, 29, 862–865. [PubMed]
28. Goto, E.; Matsumoto, Y.; Kamoi, M.; Endo, K.; Ishida, R.; Dogru, M. Tear evaporation rates in Sjögren
syndrome and non-Sjögren dry eye patients. Am. J. Ophthalmol. 2007, 144, 81–85. [CrossRef] [PubMed]
29. Nebbioso, M.; Belcaro, G.; Komaiha, C.; Celani, C.; Pescosolido, N. Keratoconjunctivitis by confocal
microscopy after topical cyclosporine. Panminerva Med. 2012, 56, 9–13.
Int. J. Mol. Sci. 2017, 18, 1764 16 of 19
30. Alhatem, B.; Cavalcanti, B.; Hamrah, P. In vivo confocal microscopy in dry eye disease and related conditions.
Semin. Ophthalmol. 2012, 27, 138–148. [CrossRef] [PubMed]
31. Villani, E.; Magnani, F.; Viola, F.; Santaniello, A.; Scorza, R.; Nucci, P.; Ratiglia, R. In vivo confocal evaluation
of the ocular surface morpho-functional unit in dry eye. Optom. Vis. Sci. 2013, 90, 576–586. [CrossRef]
[PubMed]
32. Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.;
Fox, P.C.; Fox, R.I.; Kassan, S.S.; et al. European Study Group on Classification Criteria for Sjögren's
Syndrome. Classification criteria for Sjögren syndrome: A revised version of the European criteria proposed
by the American-European consensus group. Ann. Rheum. Dis. 2002, 61, 554–558. [CrossRef] [PubMed]
33. Shiboski, S.C.; Shiboski, C.H.; Criswell, L.; Baer, A.; Challacombe, S.; Lanfranchi, H.; Schiødt, M.;
Umehara, H.; Vivino, F.; Zhao, Y.; et al. Sjögren’s International Collaborative Clinical Alliance (SICCA)
Research Groups. American college of rheumatology classification criteria for Sjogren’s syndrome:
A data-driven, expert consensus approach in the SICCA cohort. Arthritis Care Res. 2012, 64, 475–487.
[CrossRef]
34. Djalilian, A.R.; Hamrah, P.; Pflugfelder, S.C. Dry eye. In Cornea, 2nd ed.; Krachmer, J.H., Mannis, M.J.,
Holland, E.J., Eds.; Elsevier Mosby: Philadelphia, PA, USA, 2005; pp. 521–540.
35. Murray, P.I.; Rauz, S. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis,
ankylosing spondylitis, psoriatic arthritis. Best Pract. Res. Clin. Rheumatol. 2016, 30, 802–825. [CrossRef]
[PubMed]
36. Rocha, E.M.; Wickham, L.A.; da Silveira, L.A.; Krenzer, K.L.; Yu, F.S.; Toda, I.; Sullivan, B.D.;
Sullivan, D.A. Identification of androgen receptor protein and 5α-reductase mRNA in human ocular tissues.
Br. J. Ophthalmol. 2000, 84, 76–84. [CrossRef] [PubMed]
37. Nebbioso, M.; Evangelista, M.; Librando, A.; Plateroti, A.M.; Pescosolido, N. Iatrogenic dry eye disease:
An eledoisin/carnitine and osmolyte drops study. Biomed. Pharmacother. 2013, 67, 659–663. [CrossRef]
[PubMed]
38. Suzuki, T.; Richards, S.M.; Liu, S.; Jensen, R.V.; Sullivan, D.A. Influence of sex on gene expression in human
corneal epithelial cells. Mol. Vis. 2009, 15, 2554–2569. [PubMed]
39. Duarte, M.C.; Pinto, N.C.; Moreira, H.; Moreira, A.T.; Wasilewski, D. Total testosterone level in
postmenopausal women with dry eye. Arq. Bras. Oftalmol. 2007, 70, 465–469. [CrossRef] [PubMed]
40. Gonen, T.; Celik, C.; Oznur, M.; Abali, R.; Gonen, K.A.; Horozoglu, F.; Aksu, E.; Keskinbora, K.H. Tear
osmolarity and ocular surface changes in patient with polycystic ovary syndrome. Curr. Eye Res. 2013, 38,
621–625. [CrossRef] [PubMed]
41. Sriprasert, I.; Warren, D.W.; Mircheff, A.K.; Stanczyk, F.Z. Dry eye in postmenopausal women: A hormonal
disorder. Menopause 2016, 23, 343–351. [CrossRef] [PubMed]
42. Maziak, W.; Behrens, T.; Brasky, T.M.; Duhme, H.; Rzehak, P.; Weiland, S.K.; Keil, U. Are asthma and allergies
in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Münster,
Germany. Allergy 2003, 58, 572–579. [CrossRef] [PubMed]
43. Nebbioso, M.; Zicari, A.M.; Celani, C.; Lollobrigida, V.; Grenga, R.; Duse, M. Pathogenesis of vernal
keratoconjunctivitis and associated Factors. Semin. Ophthalmol. 2015, 30, 340–344. [CrossRef] [PubMed]
44. Pflugfelder, S.C.; Jones, D.; Ji, Z.; Afonso, A.; Monroy, D. Altered cytokine balance in the tear fluid and
conjunctiva of patients with Sjögren’s syndrome keratoconjunctivitis sicca. Curr. Eye Res. 1999, 19, 201–211.
[CrossRef] [PubMed]
45. Wang, Y.; Le, Q.; Zhao, F.; Hong, J.; Xu, J.; Zheng, T.; Sun, X. Application of in vivo laser scanning confocal
microscopy for evaluation of ocular surface diseases: Lessons learned from pterygium, meibomian gland
disease, and chemical burns. Cornea 2011, 30, S25–S28. [CrossRef] [PubMed]
46. Ibrahim, O.M.; Matsumoto, Y.; Dogru, M.; Adan, E.S.; Wakamatsu, T.H.; Shimazaki, J.; Fujishima, H.; Tsubota, K.
In vivo confocal microscopy evaluation of Meibomian gland dysfunction in atopic-keratoconjunctivitis patients.
In Proceedings of the 64th Congress of Clinical Ophthalmology of Japan, Kobe, Japan, 12 November 2010.
47. Nebbioso, M.; Zicari, A.M.; Lollobrigida, V.; Marenco, M.; Duse, M. Assessment of corneal alterations by
confocal microscopy in vernal keratoconjunctivitis. Semin. Ophthalmol. 2015, 30, 40–43. [CrossRef] [PubMed]
48. Battar, L.; Macri, A.; Dursun, D.; Pflugfelder, S.C. Effects of laser in situ keratomileusis on tear production,
clearance, and the ocular surface. Ophthalmology 2001, 108, 1230–1235. [CrossRef]
Int. J. Mol. Sci. 2017, 18, 1764 17 of 19
49. Li, X.M.; Hu, L.; Hu, J.; Wang, W. Investigation of dry eye disease and analysis of the pathogenic factors in
patients after cataract surgery. Cornea 2007, 26, S16–S20. [CrossRef] [PubMed]
50. Yu, E.Y.; Leung, A.; Rao, S.; Lam, D.S. Effect of laser in situ keratomileusis on tear stability. Ophthalmology
2000, 107, 2131–2135. [CrossRef]
51. De Paiva, C.S.; Chen, Z.; Koch, D.D.; Hamill, M.B.; Manuel, F.K.; Hassan, S.S.; Wilhelmus, K.R.;
Pflugfelder, S.C. The incidence and risk factors for developing dry eye after myopic Lasik. Am. J. Ophthalmol.
2006, 141, 438–445. [CrossRef] [PubMed]
52. Stephenson, C.G.; Gartry, D.S.; O’Brart, D.P.; Kerr-Muir, M.G.; Marshall, J. Photorefractive keratectomy.
A 6 year follow-up study. Ophthalmology 1998, 105, 273–281. [CrossRef]
53. Rajan, M.S.; Jaycock, P.; O’Brart, D.; Nystrom, H.H.; Marshall, J. A long-term study of photorefractive
keratectomy, 12-year follow-up. Ophthalmology 2004, 111, 1813–1824. [PubMed]
54. Albietz, J.M.; Lenton, L.M.; Mc Lennan, S.G. Effect of laser in situ keratomileusis for hyperopia on tear film
and ocular surface. J. Refract. Surg. 2002, 18, 113–123. [PubMed]
55. Ambrosio, R.; Tervo, T., Jr.; Wilson, S.E. Lasik-associated dry eye and neurotrophic epitheliopathy:
Pathophysiology and strategies for prevention and treatment. J. Refract. Surg. 2008, 24, 396–407. [PubMed]
56. Richardson, J.D.; Vasko, M.R. Cellular mechanism of neurogenic infiammation. Pharmacol. Exp. Ther. 2002,
302, 839–845. [CrossRef] [PubMed]
57. Wilson, S.E. Analysis of the keratocyte apoptotis, keratocyte profileration and myofibroblast transormation
responses after photorefractive keratectomy and laser in situ keratomileusis. Trans. Am. Ophthalmol. Soc.
2002, 100, 411–433. [PubMed]
58. Alio, J.L.; Javaloy, J. Corneal infiammation following corneal photoablative refractive surgery with excimer
laser. Ophthalmology 2013, 58, 11–25.
59. Patel, S.; Perez-Santonja, J.J.; Alio, J.L.; Murphy, P.J. Corneal Sensitivity and some properties of the tear film
after laser in situ keratomileusis. J. Refract. Surg. 2001, 17, 17–24. [PubMed]
60. Toda, I. LASIK and dry eye. Compr. Ophthalmol. Update 2007, 8, 79–89. [PubMed]
61. Ueta, M.; Sotozono, C.; Inatomi, T.; Kojima, K.; Tashiro, K.; Hamuro, J.; Kinoshita, S. Toll-like receptor 3 gene
polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br. J. Ophthalmol. 2007, 91, 962–965.
[CrossRef] [PubMed]
62. Jain, R.; Sharma, N.; Basu, S.; Iyer, G.; Ueta, M.; Sotozono, C.; Kannabiran, C.; Rathi, V.M.; Gupta, N.;
Kinoshita, S.; et al. Stevens-Johnson syndrome: The role of an ophthalmologist. Surv. Ophthalmol. 2016, 61,
369–399. [CrossRef] [PubMed]
63. Kohanim, S.; Palioura, S.; Saeed, H.N.; Akpek, E.K.; Amescua, G.; Basu, S.; Blomquist, P.H.; Bouchard, C.S.;
Dart, J.K.; Gai, X. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal
necrolysis—A comprehensive review and guide to therapy. II. Ophthalmic disease. Ocul. Surf. 2016, 14,
168–188. [CrossRef] [PubMed]
64. Carracedo, G.; Recchioni, A.; Alejandre-Alba, N.; Martin-Gil, A.; Crooke, A.; Jimenez-Alfaro Morote, I.;
Pintor, J. Signs and symptoms of dry eye in keratoconus patients: a pilot study. Curr. Eye Res. 2015, 40,
1088–1094. [CrossRef] [PubMed]
65. Dienes, L.; Kiss, H.J.; Nagy, Z.Z.; Acosta, M.C.; Gallar, J.; Kovacs, I. Corneal sensitivity and dry eye symptoms
in patients with keratoconus. PLoS ONE 2015, 10, e0141621. [CrossRef] [PubMed]
66. Cho, K.J.; Mok, J.W.; Choi, M.Y.; Kim, J.Y.; Joo, C.K. Changes in corneal sensation and ocular surface in
patients with asymmetrical keratoconus. Cornea 2013, 32, 205–210. [CrossRef] [PubMed]
67. Al-Aquaba, M.A.; Faraj, L.; Fares, U.; Otri, A.M.; Dua, H.S. The morphologic characteristics of corneal nerves
in advanced keratoconus as evaluated by acetylcholinesterase technique. Am. J. Ophthalmol. 2011, 152,
364–376. [CrossRef] [PubMed]
68. Lema, I.; Duran, J.A. Infiammatory molecules in the tears of patients with keratoconus. Ophthalmology 2005,
112, 645–649. [CrossRef] [PubMed]
69. Di Girolamo, N.; Chui, J.; Coroneo, M.T.; Wakeeld, D. Pathogenesis of pterygia: Role of cytokines, growth
factors, and matrix metalloproteinases. Progr. Retin. Eye Res. 2004, 23, 195–228. [CrossRef] [PubMed]
70. Detorakis, E.T.; Zaravinos, A.; Spandidos, D.A. Growth factor expression in ophthalmic pterygia and normal
conjunctiva. Int. J. Mol. Med. 2010, 25, 513–516. [CrossRef] [PubMed]
71. Li, D.; Chen, Z.; Song, J.; Luo, L.; Pugfelder, S.C. Stimulation of matrix metalloproteinases by hyperosmolarity
via a JNK pathway in human corneal epithelial cells. Investig. Ophthalmol. Vis Sci. 2004, 45, 4302–4311.
Int. J. Mol. Sci. 2017, 18, 1764 18 of 19
72. Li, M.; Zhang, M.; Lin, Y.; Xiao, Q.; Zhu, Z.; Song, S.; Lin, J.; Chen, J.; Liu, Z. Tear function and goblet cell
density after pterygium excision. Eye 2007, 21, 224–228. [CrossRef] [PubMed]
73. Guzman-Aranguez, A.; Gasull, X.; Diebold, Y.; Pintor, J. Purinergic receptors in ocular inflammation.
Med. Inflamm. 2014, 2014, 320906. [CrossRef] [PubMed]
74. Arciniega, J.C.; Nadji, E.J.; Butovich, I.A. Effects of free fatty acids on Meibomian lipid films. Exp. Eye Res.
2011, 93, 452–459. [CrossRef] [PubMed]
75. Kenchegowda, S.; Bazan, H.E. Significance of lipid mediators in corneal injury and repair. J. Lipid Res. 2010,
51, 879–891. [CrossRef] [PubMed]
76. Wang, S.B.; Hu, K.M.; Seamon, K.J.; Mani, V.; Chen, Y.; Gronert, K. Estrogen negatively regulates epithelial
wound healing and protective lipid mediator circuits in the cornea. FASEB J. 2012, 26, 1506–1516. [CrossRef]
[PubMed]
77. Leedom, A.J.; Sullivan, A.B.; Dong, B.; Lau, D.; Gronert, K. Endogenous LXA4 circuits are determinants of
pathological angiogenesis in response to chronic injury. Am. J. Pathol. 2010, 176, 74–84. [CrossRef] [PubMed]
78. Biteman, B.; Hassan, I.R.; Walker, E.; Leedom, A.J.; Dunn, M.; Seta, F.; Laniado-Schwartzman, M.; Gronert, K.
Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal
wound healing. FASEB J. 2007, 21, 2257–2266. [CrossRef] [PubMed]
79. Gao, Y.; Min, K.J.; Zhang, Y.B.; Su, J.; Greenwood, M.; Gronert, K. Female-specific down-regulation of tissue
polymorphonuclear neutrophils drives impaired regulatory T cell and amplified effector T cell responses in
autoimmune dry eye disease. J. Immunol. 2015, 195, 3086–3099. [CrossRef] [PubMed]
80. Mukherjee, P.K.; Marcheselli, V.L.; Serhan, C.N.; Bazan, N.G. Neuro-protectin D1: A docosahexaenoic
acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl.
Acad. Sci. USA 2004, 101, 8491–8496. [CrossRef] [PubMed]
81. Cortina, M.S.; He, J.; Li, N.; Bazan, N.G.; Bazan, H.E. Recovery of corneal sensitivity, calcitonin gene-related
peptide-positive nerves, and increased wound healing induced by pigment epithelial-derived factor plus
docosahexaenoic acid after experimental surgery. Arch. Ophthalmol. 2012, 130, 76–83. [CrossRef] [PubMed]
82. Cortina, M.S.; He, J.; Li, N.; Bazan, N.G.; Bazan, H.E. Neuroprotectin D1 synthesis and corneal nerve
regeneration after experimental surgery and treatment with PEDF plus DHA. Investig. Ophthalmol. Vis. Sci.
2010, 51, 804–810. [CrossRef] [PubMed]
83. Serhan, C.N. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving
lipid mediators and pathways. Annu. Rev. Immunol. 2007, 25, 101–137. [CrossRef] [PubMed]
84. Li, N.; He, J.; Schwartz, C.E.; Gjorstrup, P.; Bazan, H.E. Resolvin E1 improves tear production and decreases
inflammation in a dry eye mouse model. J. Ocul. Pharmacol. Ther. 2010, 26, 431–439. [CrossRef] [PubMed]
85. Liu, X.; Wang, S.; Kao, A.A.; Long, Q. The effect of topical pranoprofen 0.1% on the clinical evaluation and
conjunctival HLA-DR expression in dry eyes. Cornea 2012, 31, 1235–1239. [CrossRef] [PubMed]
86. Fujishima, H.; Fuseya, M.; Ogata, M.; Murat, D. Efficacy of bromfenac sodium ophtlamic solution for
treatment of dry eye disease. Asia Pac. J. Ophtalmol. (Phila.) 2015, 4, 9–13. [CrossRef] [PubMed]
87. Nassar, A.; Tabbara, K.F.; Aljurf, M. Ocular manifestations of graft versus disease. Saudi J. Opthalmol. 2013,
27, 215–222. [CrossRef] [PubMed]
88. Schmidt, T.A.; Sullivan, D.A.; Knop, E.; Richards, S.M.; Knop, N.; Liu, S.; Sahin, A.; Darabad, R.R.;
Morrison, S.; Kam, W.R.; Sullivan, B.D. Transcription, translation, and function of lubricin, a boundary
lubricant, at the ocular surface. JAMA Ophthalmol. 2013, 13, 766–776. [CrossRef] [PubMed]
89. Samsom, M.L.; Morrison, S.; Masala, N.; Sullivan, B.D.; Sullivan, D.A.; Sheardown, H.; Schmidt, T.A.
Characterization of full-length recombinant human Proteoglycan 4 as an ocular surface boundary lubricant.
Exp. Eye Res. 2014, 127, 14–19. [CrossRef] [PubMed]
90. Lambiase, A.; Sullivan, B.D.; Schmidt, T.A.; Sullivan, D.A.; Jay, G.D.; Truitt, E.R., 3rd; Bruscolini, A.;
Sacchetti, M.; Mantelli, F. A two-week, randomized, double-masked study to evaluate safety and efficacy of
lubricin (150 µg/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed®) in patients
with moderate dry eye disease. Ocul. Surf. 2016, 15, 77–87. [CrossRef] [PubMed]
91. Meerovitch, K.; Torkildsen, G.; Lonsdale, J.; Goldfarb, H.; Lama, T.; Cumberlidge, G.; Ousler, G.W., 3rd.
Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled phase 2 clinical
trial in patients with dry eye. Clin. Ophthalmol. 2013, 7, 1275–1285. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1764 19 of 19
92. Bremond-Gignac, D.; Gicquel, J.J.; Chiambaretta, F. Pharmacokinetic evaluation of diquafosol tetrasodium
for the treatment of Sjögren’s syndrome. Expert Opin. Drug. Metab. Toxicol. 2014, 10, 905–913. [CrossRef]
[PubMed]
93. Stevenson, W.; Chauhan, S.K.; Dana, R. Dry eye disease: An immune-mediated ocular surface disorder.
Arch. Ophthalmol. 2012, 130, 90–100. [CrossRef] [PubMed]
94. Wan, K.H.; Chen, L.J.; Young, A.L. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment
of dry eye syndrome: A systematic review and meta-analysis. Ocul. Surf. 2015, 13, 213–225. [CrossRef]
[PubMed]
95. Semba, C.P.; Torkildsen, G.L.; Lonsdale, J.D.; McLaurin, E.B.; Geffin, J.A.; Mundorf, T.K.; Kennedy, K.S.;
Ousler, G.W. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist
(sar 1118) for the treatment of dry eye. Am. J. Ophthalmol. 2012, 153, 1050–1060. [CrossRef] [PubMed]
96. Zhou, X.Q.; Wei, R.L. Topical cyclosporine a in the treatment of dry eye: A systematic review and
meta-analysis. Cornea 2014, 33, 760–767. [CrossRef] [PubMed]
97. Agarwal, P.; Rupenthal, I.D. Modern approaches to the ocular delivery of cyclosporine A. Drug Discov. Today
2016, 21, 977–988. [CrossRef] [PubMed]
98. Perez, V.L.; Pflugfelder, S.C.; Zhang, S.; Shojaei, A.; Haque, R. Lifitegrast, a novel integrin antagonist for
treatment of dry eye disease. Ocul. Surf. 2016, 14, 207–215. [CrossRef] [PubMed]
99. Sada, P.R.; Isenberg, D.; Ciurtin, C. Biologic treatment in Sjögren’s syndrome. Rheumatology 2015, 54, 219–230.
[CrossRef] [PubMed]
100. St Clair, E.W.; Levesque, M.C.; Prak, E.T.; Vivino, F.B.; Alappatt, C.J.; Spychala, M.E.; Wedgwood, J.;
McNamara, J.; Moser Sivils, K.L.; Fisher, L.; et al. Autoimmunity centers of excellence. Rituximab therapy
for primary Sjögren’s syndrome: An open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013,
65, 1097–1106. [CrossRef] [PubMed]
101. Nebbioso, M.; Rusciano, D.; Pucci, B.; Zicari, A.M.; Grenga, R.; Pescocolido, N. Treatment of glaucomatous
patients by means of food supplement to reduce the ocular discomfort: A double blind randomized trial.
Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 1117–1122. [PubMed]
102. Pescosolido, N.; Giannotti, R.; Plateroti, A.M.; Pascarella, A.; Nebbioso, M. Curcumin: Therapeutical potential
in ophthalmology. Planta Med. 2014, 80, 249–254. [CrossRef] [PubMed]
103. Li, W.; Chen, Y.T.; Hayashida, Y.; Blanco, G.; Kheirkah, A.; He, H.; Chen, S.Y.; Liu, C.Y.; Tseng, S.C.
Down-regulation of PAX6 is associated with abnormal differentiation of corneal epithelial cells in severe
ocular surface diseases. J. Pathol. 2008, 214, 114–122. [CrossRef] [PubMed]
104. Ouyang, H.; Goldberg, J.L.; Chen, S.; Li, W.; Xu, G.T.; Li, W.; Zhang, K.; Nussenblatt, R.B.; Liu, Y.; Xie, T.; et al.
Ocular stem cell research from basic science to clinical application: A report from zhongshan ophthalmic
center ocular stem cell symposium. Int. J. Mol. Sci. 2016, 17, 415. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
